Ocular Therapeutix (OCUL) Competitors $11.84 -0.36 (-2.95%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$11.84 0.00 (0.00%) As of 10/17/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OCUL vs. ABVX, RNA, CYTK, MRUS, RYTM, CRSP, GRFS, NUVL, AXSM, and LEGNShould you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Merus (MRUS), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Grifols (GRFS), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Ocular Therapeutix vs. Its Competitors Abivax Avidity Biosciences Cytokinetics Merus Rhythm Pharmaceuticals CRISPR Therapeutics Grifols Nuvalent Axsome Therapeutics Legend Biotech Abivax (NASDAQ:ABVX) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Which has more volatility & risk, ABVX or OCUL? Abivax has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Which has better earnings & valuation, ABVX or OCUL? Abivax has higher earnings, but lower revenue than Ocular Therapeutix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbivaxN/AN/A-$190.71MN/AN/AOcular Therapeutix$63.72M32.33-$193.51M-$1.28-9.25 Do institutionals & insiders hold more shares of ABVX or OCUL? 47.9% of Abivax shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer ABVX or OCUL? In the previous week, Abivax had 4 more articles in the media than Ocular Therapeutix. MarketBeat recorded 9 mentions for Abivax and 5 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.83 beat Abivax's score of 0.44 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ABVX or OCUL more profitable? Abivax has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Abivax's return on equity of 0.00% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets AbivaxN/A N/A N/A Ocular Therapeutix -382.51%-71.92%-49.36% Do analysts rate ABVX or OCUL? Abivax currently has a consensus price target of $114.25, suggesting a potential upside of 23.21%. Ocular Therapeutix has a consensus price target of $22.63, suggesting a potential upside of 91.09%. Given Ocular Therapeutix's higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91Ocular Therapeutix 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryAbivax and Ocular Therapeutix tied by winning 7 of the 14 factors compared between the two stocks. Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUL vs. The Competition Export to ExcelMetricOcular TherapeutixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.12B$2.63B$6.09B$10.48BDividend YieldN/A57.79%5.73%4.80%P/E Ratio-9.2522.9984.5227.09Price / Sales32.33552.73521.80181.08Price / CashN/A168.7137.1661.22Price / Book5.895.3212.246.52Net Income-$193.51M$33.06M$3.32B$276.75M7 Day Performance0.51%2.44%1.25%1.97%1 Month Performance-6.85%6.46%6.28%2.23%1 Year Performance4.50%-5.42%59.92%35.58% Ocular Therapeutix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCULOcular Therapeutix4.3219 of 5 stars$11.84-3.0%$22.63+91.1%+6.8%$2.12B$63.72M-9.25230Gap DownABVXAbivax3.5043 of 5 stars$95.63+2.0%$114.25+19.5%+795.9%$7.30BN/A0.0061Short Interest ↓RNAAvidity Biosciences2.5493 of 5 stars$48.96-1.6%$68.32+39.5%-1.3%$7.26B$10.90M-13.75190News CoverageInsider TradeCYTKCytokinetics3.8489 of 5 stars$59.59-0.7%$76.64+28.6%+7.2%$7.18B$18.47M-11.68250Trending NewsInsider TradeMRUSMerus1.402 of 5 stars$94.85+0.5%$93.12-1.8%+83.4%$7.14B$36.13M-17.2537Short Interest ↓RYTMRhythm Pharmaceuticals2.8904 of 5 stars$100.770.0%$106.64+5.8%+116.1%$6.70B$130.13M-33.48140News CoverageAnalyst ForecastCRSPCRISPR Therapeutics2.2295 of 5 stars$68.29-6.5%$71.71+5.0%+43.2%$6.65B$37.31M-12.58460Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionGRFSGrifols3.764 of 5 stars$9.45+1.4%$10.30+9.0%+12.3%$6.41B$7.81B8.0823,822NUVLNuvalent2.8066 of 5 stars$89.75+1.9%$118.89+32.5%-9.4%$6.35BN/A-18.3240Trending NewsAnalyst ForecastInsider TradeAXSMAxsome Therapeutics4.73 of 5 stars$121.15-0.5%$177.93+46.9%+37.1%$6.07B$385.69M-23.90380Analyst RevisionLEGNLegend Biotech3.0544 of 5 stars$32.85+3.6%$69.25+110.8%-25.8%$5.85B$627.24M-37.332,609News CoverageAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies ABVX Competitors RNA Competitors CYTK Competitors MRUS Competitors RYTM Competitors CRSP Competitors GRFS Competitors NUVL Competitors AXSM Competitors LEGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCUL) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
